Explore the updated programme
Dear HIFA,
Our free GPC 2023 to be held on 19 - 20 May 2023 at the Maison Internationale des Associations (MIA) in Geneva, Switzerland as a hybrid event from 8am CEST is now just 1 day away.
This year's theme is "Innovative patient partnerships at the heart of global health advancement". The Congress is co-hosted by IAPO - International Alliance of Patients' Organizations in collaboration with IAPO Patients for Patient Safety Observatory.
Join us to: [https://gpc2023.pincrowdevents.com/register.html]
celebrate and advocate for innovative and meaningful patient partnerships to be placed at the heart of all build back better healthcare planshear balanced and honest views from our policy experts about the opportunities available for innovative patient partnerships for global health advancementdiscuss the next steps in building back better an innovative and sustainable Universal Health Coverage that is safe, accessible, affordable, acceptable, and equitable.
Join hundreds of attendees, including patient representatives, chief executives of patient organizations, carers, civil society, policy makers, academia and healthcare industry representatives.
Find out more and register [https://www.iapo.org.uk/global-patients-congress]
Hear from the experts: GPC 2023 sessions and speakers
Promoting novel patient partnerships in research and development of innovative medicines and health devices
This session will go deep into the details of the new agilities developed during the pandemic in medicines development and authorisation life cycles focusing on how we got new innovative medicines within one year of disease appearing without compromising safety. We will reflect on the public, private and societal/patient partnership that developed and found new agilities in medicines and health technology research and development. This is will also be a moment to reflect upon the lessons learnt for the future in improving the process of researching and developing innovative medicines and health devices that treat the disease and meet the needs of patients effectively, efficiently and in a patient-centred manner. With the focus shifting away from the medicine/product and on to patient experiences, perspectives, needs, and priorities, this session will look at why and how patients need to engage in medicine and health devices research and development.
Developing robust and resilient patient partnerships with health professionals to promote patient-centred, compassionate and humanised healthcare
Robust and innovative ‘patient- health professional’ partnerships are transforming the healthcare landscape and ecosystem. Today, patients are working with professional associations in a meaningful way to influence health professional education, training, and relationships. The benefits are to both partners and impacts patient outcomes and experience and ensures equity. This session will look at why patient partnerships with doctors, nurses, and other health professionals are important at all levels of healthcare systems, and how they can impact upon both the patient outcomes and health professional esteem, welfare, health and wellbeing. This session will also look at the best partnership examples and reflect on models proposed after the pandemic.
Evolving novel patient partnerships in genomic personalised medicine and digital health- AI and machine learning
This session will look at the many innovative disrupter health technologies that have emerged from the convergence of genomic medicine with artificial intelligence and digital healthcare solutions and how these health technologies will help in delivering compassionate and humanised healthcare. With IAPO active in the Personalised Cancer Care Alliance (PCCA) and contributing to a PCCA position paper that advocates greater State investment to boost economies of scale in the adoption of genomic medicine, digital health, artificial intelligence, machine learning and other health technologies, this session will explore how patient partnerships can help in initiating personalised healthcare and how this can help early diagnosis and prevention of diseases.
Building national innovative patient and family partnerships in support of the Global Patient Safety Action Plan: Tomorrows safe primary healthcare, hospitals and health facilities
The World Health Organization (WHO)’s Global Patient Safety Action Plan 2021-30 (GPSAP) aims to ensure that we are delivering a safe universal health coverage by ensuring all our health systems reduce all avoidable patient harm to zero by 2030. The Plan recognises that patient safety is everyone’s responsibility. This means that patient organisations, healthcare providers, regulators, medicines and devices manufacturers, professional bodies, academia and the government must work together in innovative partnerships. Meaningful patient and family engagement in patient safety is one of the main pillars of the GPSAP. This session will look at what constitutes a good patient, family and health institute partnership. We will also explore what action each stakeholder must take to make our health systems and the universal health coverage safe for all.
Emphasizing the critical need for patient partnerships in medicines and health devices regulation
For compassionate, humanised, and patient centric healthcare to happen, we must ensure that the entire healthcare value chain delivers services, medicines and health devices that are of high quality, safe and effective. Medicines and health devices regulators can ensure that this happens. Market authorisation of innovative medicines and health devices needs to happen at the same pace and time globally to prevent regional inequity which develops if medicines approval is delayed in some countries, while others have advanced. COVID-19 vaccines market authorisations delays revealed to us how this inequity can impact our health and wellbeing. During the pandemic, the value of regulatory reliance and early and thorough regulatory approval of innovative and repurposed medicines was critical. This required a whole of government, industry, and patient community partnership with their national medicines regulatory authority. The best outcomes were achieved in regions where new agilities were developed and innovative medicines regulatory pathways created. The lessons learnt, and new structures developed during the emergency must be leveraged now for routine situations to improve patients’ early access to innovative, quality, and safe medicines globally.
The session will explore how regulatory reliance benefit patients and how patient partnerships advance the regulatory process into delivering safe and high-quality diagnostics, vaccines, and treatments to patients as fast as possible.
Re-invigorating ‘patient-state’ partnerships in reorienting universal health coverage through primary healthcare community pharmacies and self-care
When in 2017 the United Nations (UN) declared 12 December as International Universal Health Coverage (UHC) Day, we had high-level commitment made to the UHC vision that all people have access to the full range of quality health services they need, when and where they need them, without financial hardship. This commitment was further endorsed by the UN in 2019 at the United Nations High-Level Meeting (UN HLM) “UHC: Moving Together to Build a Healthier World”, where Member States agreed to ensure that by 2030 everyone in their country will receive all the quality health services they need without suffering financial hardship. Now, post pandemic, the World Health Organization (WHO)’s Executive Board 152 in January 2023 shared a road map for reorienting health systems to primary healthcare (PHC) as a resilient foundation for universal health coverage.
This session will look at the several UN High-Level Political Declarations and WHO Resolutions on UHC and PHC and where we are with them. It will also look at how we can boost self-care and the key role community pharmacists play in making UHC complete.
Opening health economics, HTA and value-based healthcare to patient partnerships
Health is a political choice made in severe economic climates today. The choices to invest in universal health coverage (UHC) are being made within a complex post-COVID competing interests. Over the last decade, there has been an explosion of genomic and digital health technologies available to all and it is now extremely difficult to make the best choice. How will Member States procure all the innovative evidence-based medicines, services, health devices and other health technologies available to extend their UHC 2030 to cover most of their population, give them more appropriate and effective standard and personalised healthcare services and medicines, and reduce their out-of-pocket contributions within the national budget?
This session will look at how we can improve access to innovative medicines through patient engagement and advocacy activity in health technology assessment (HTA) and value-based healthcare (VBHC) approaches.
See the full programme [https://www.iapo.org.uk/node/15610] [http://iapo.org.uk] Share https://iapo.cmail19.com/t/d-fb-vlrnik-iuqjytrli-c/ Tweet https://iapo.cmail19.com/t/d-tw-vlrnik-iuqjytrli-q/ Share [https://iapo.cmail19.com/t/d-li-vlrnik-iuqjytrli-n/] Forward https://iapo.forwardtomyfriend.com/d-iuqjytrli-D73DF6B4-vlrnik-l-a info@iapo.org.uk | +44 20 7250 8280
49-51 East Road, London N1 6AH, United Kingdom
Company no. 8495711 | Registered charity no. 1155577 Preferences https://iapo.updatemyprofile.com/d-vlrnik-D73DF6B4-iuqjytrli-f | Unsubscribe https://iapo.cmail19.com/t/d-u-vlrnik-iuqjytrli-z/
